VHCP Management’s CytomX Therapeutics CTMX Stock Holding History

VHCP Management’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$706K	Hold	64,200	–	–	0.76%	18
2016 Q3	$1.01M	Hold	64,200	–	–	0.99%	20
2016 Q2	$656K	Hold	64,200	–	–	0.68%	20
2016 Q1	$828K	Sell	64,200 -10,800	-14%	-$150K	0.72%	20
2015 Q4	$1.56M	Buy	+75,000	New	+$1.19M	0.95%	18

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

VHCP Management's CTMX Position: Q4 2016 in Review

VHCP Management held its CytomX Therapeutics (CTMX) position steady in Q4 2016 at 64,200 shares worth $706K. The position accounts for 0.76% of the portfolio, ranked #18.

VHCP Management first reported a position in CTMX in Q4 2015 and has held it in 5 quarters since. The position peaked at $1.56M in Q4 2015. 68 funds tracked by Wall St. Rank hold CTMX as of Q4 2016.

VHCP Management held 64,200 shares of CytomX Therapeutics worth $706K as of Q4 2016.
VHCP Management left its CytomX Therapeutics share count unchanged in Q4 2016.
CytomX Therapeutics made up 0.76% of VHCP Management's portfolio in Q4 2016, its #18 holding.
VHCP Management first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 5 quarters since.
VHCP Management's CytomX Therapeutics position peaked at $1.56M in Q4 2015.
68 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2016.

Based on VHCP Management's 13F filing for Q4 2016, filed 13 Feb 2017.